Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriTEN antibody
- Development stage
- Preclinical
- Lead developer
- Guangzhou Jinan Biomedical Research and Development Base
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TriTEN antibody is a trispecific T-cell engager (TCE) currently in preclinical development by the Guangzhou Jinan Biomedical Research and Development Base for the treatment of cancer. The antibody is designed to simultaneously bind three targets: the CD3 epsilon subunit and the CD28 costimulatory receptor on T cells, and a tumor-associated antigen (TAA) on malignant cells. By engaging both CD3 (Signal 1) and CD28 (Signal 2), TriTEN aims to provide a more complete activation signal to T cells compared to traditional bispecific engagers, potentially enhancing anti-tumor efficacy, T-cell proliferation, and persistence within the tumor microenvironment. This trispecific approach is intended to drive potent, tumor-specific immune responses while minimizing systemic toxicity.
- Other names
- trispecific T-cell engager
02
Targets
CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on TriTEN antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriTEN antibody.